EDGAR·FLOW

Vanda Pharmaceuticals Inc. — Form 8-K

Filed November 20, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 28/100
What the filing says
Vanda Pharmaceuticals filed an 8-K on 2026-11-16 disclosing entry into a Material Definitive Agreement (Item 1.01). The filing header confirms the event but provides no substantive details: no counterparty name, dollar amounts, deal terms, or business description are disclosed in the available document text. The actual agreement details and exhibits are referenced but not included in this filing extract.
Why this rating

Cannot assess magnitude without agreement details. For a $269M company, materiality depends entirely on unknown deal size and strategic importance. Routine disclosure only.

Extracted items
View original filing on SEC.gov ↗ VNDA · stock on Yahoo Finance ↗

See more from November 20, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.